stockportfolio.pro
Stocks / OMER vs ZVRA
OMER vs ZVRA
Omeros Corporation and Zevra Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Omeros Corporation (OMER) | Zevra Therapeutics, Inc. (ZVRA) | |
|---|---|---|
| Market cap | $0.7B | $0.8B |
| Revenue (latest FY) | $0 | $106.47M |
| Net income (latest FY) | $-3.35M | $83.23M |
| Revenue growth (5y CAGR) | — | 51.6% |
| Net margin | — | 78.2% |
| Return on equity | 2.8% | 53.8% |
| P/E ratio | 9.0 | 6.4 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 2 | 1 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open OMER — free Open ZVRA — freeFrequently asked questions
Which is bigger, OMER or ZVRA?
Zevra Therapeutics, Inc. is larger by market capitalization — $0.8B versus $0.7B.
Which grows faster, OMER or ZVRA?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.